Trump's presidency return: boom or bust for biopharmaceutical deal activity?

By Yahoo! Finance   |   1 year ago
Trump's presidency return: boom or bust for biopharmaceutical deal activity?

Donald Trump's re-election in 2024 may impact biopharmaceutical M&A activity due to potential changes in FTC leadership and policies. His 'America First' stance and healthcare policy uncertainties could affect the industry's future growth and innovation.

Read More

Did you find this insightful?